更新于：2024-11-04
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
211
项与 盐酸帕罗西汀 相关的临床试验The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,563
项与 盐酸帕罗西汀 相关的文献（医药）2024-11-21Journal of sex research
No Magic Pill: A Systematic Review of the Pharmacological Treatments for Compulsive Sexual Behavior Disorder
Review
作者: Owen, Tyler ; Kraus, Shane W. ; Borgogna, Nicholas C. ; Johnson, David
Compulsive sexual behavior disorder (CSBD) is a burgeoning diagnostic construct. No systematic reviews of CSBD pharmacotherapy interventions have been conducted. We addressed this gap using a three-aim approach. We reviewed researchers' theoretical arguments for various pharmacotherapies, outcomes from pharmacotherapy trials, and the generalizability of the extant findings. Our review included k = 13 studies, with n = 141 participants. An opioid model of reward seeking was the most popular framework, though inconsistently specified. A serotonin model was also documented, though with few details. Naltrexone was the most prominently examined pharmacotherapy and the only medication that reliably demonstrated a therapeutic effect for some (but not all) indicators compared to placebo. Paroxetine and citalopram were also documented in placebo-controlled trials, though their incremental benefit compared to placebo is suspect. Several additional pharmacotherapies have been documented in case series contexts. Across studies, only one female participant was identified. All trials were conducted in developed nations, and race was rarely assessed. We conclude that the case for pharmacotherapy for CSBD is limited and should preferably not occur outside of clinical trial contexts. Naltrexone offers the best evidence for a potential research program, though new theoretically informed approaches are welcome. Finally, we call for additional pharmacotherapy research in women and non-White populations.
2024-10-01Molecular neurobiology
Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression
Article
作者: Yu, Lamei ; Jin, Yuhua ; Li, Yan
The aim of this study is to explore paroxetine's effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-six patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. The levels of NGF, NT-4, BDNF, 5-hydroxytryptamine (5-HT), homocysteine (Hcy), noradrenaline (NE), Hamilton Depression Scale (HAMD) changes of National Institute of Health Stroke Scale (NIHSS). NGF, NT-4, and BDNF levels were compared between groups at T0, T1, and T2 levels were higher, and the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); NGF, NT-4, and BDNF levels were compared among groups, time, and interaction. 5-HT, Hcy, and NE levels at T0 were compared between groups; 5-HT and NE levels at T1 and T2 were higher than those at T0, the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); Hcy level at T1 and T2 was lower, its level at T2 was lower than those at T1, and observation group levels were lower (P < 0.05); 5-HT, Hcy, and NE levels were compared among groups, time, and interaction (P < 0.05). HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.
2024-09-01Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Rebound activation of 5-HT neurons following SSRI discontinuation
Article
作者: Sharp, Trevor ; Ozdemir, Dersu ; Gullino, L Sophie ; Bannerman, David M ; Pinacho, Raquel ; Sudarikova, Yulia ; Collins, Helen M ; Lazarenco, Caroline ; Daly, Elizabeth ; Pilar Cuéllar, Fuencisla
Abstract:
Cessation of therapy with a selective serotonin (5-HT) reuptake inhibitor (SSRI) is often associated with an early onset and disabling discontinuation syndrome, the mechanism of which is surprisingly little investigated. Here we determined the effect on 5-HT neurochemistry of discontinuation from the SSRI paroxetine. Paroxetine was administered repeatedly to mice (once daily, 12 days versus saline controls) and then either continued or discontinued for up to 5 days. Whereas brain tissue levels of 5-HT and/or its metabolite 5-HIAA tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus. In microdialysis experiments continuous paroxetine elevated hippocampal extracellular 5-HT and this effect fell to saline control levels on discontinuation. However, depolarisation (high potassium)-evoked 5-HT release was reduced by continuous paroxetine but increased above controls post-discontinuation. Extracellular hippocampal 5-HIAA also decreased during continuous paroxetine and increased above controls post-discontinuation. Next, immunohistochemistry experiments found that paroxetine discontinuation increased c-Fos expression in midbrain 5-HT (TPH2 positive) neurons, adding further evidence for a hyperexcitable 5-HT system. The latter effect was recapitulated by 5-HT1A receptor antagonist administration although gene expression analysis could not confirm altered expression of 5-HT1A autoreceptors following paroxetine discontinuation. Finally, in behavioural experiments paroxetine discontinuation increased anxiety-like behaviour, which partially correlated in time with the measures of increased 5-HT function. In summary, this study reports evidence that, across a range of experiments, SSRI discontinuation triggers a rebound activation of 5-HT neurons. This effect is reminiscent of neural changes associated with various psychotropic drug withdrawal states, suggesting a common unifying mechanism.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 97 | 製繭壓淵積遞膚憲網遞(構願範襯築鬱築築夢憲) = 鹹鑰襯壓醖構積齋獵膚 範餘夢願鏇構繭鏇壓壓 (餘鹹膚簾簾獵壓觸願蓋 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 製繭壓淵積遞膚憲網遞(構願範襯築鬱築築夢憲) = 願願築願夢製遞餘觸憲 範餘夢願鏇構繭鏇壓壓 (餘鹹膚簾簾獵壓觸願蓋 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 蓋鑰鬱鬱簾衊鬱醖獵鬱(齋淵範鏇壓簾簾衊壓醖) = 衊網願醖網範製艱艱鬱 鹹齋襯鏇鹽淵願醖願網 (餘繭糧淵齋夢壓簾衊廠, 衊襯鹽鬱淵繭遞範願憲 ~ 窪鏇簾繭積築構鹽壓製) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 蓋鑰鬱鬱簾衊鬱醖獵鬱(齋淵範鏇壓簾簾衊壓醖) = 艱範淵壓鏇鏇鹹構淵醖 鹹齋襯鏇鹽淵願醖願網 (餘繭糧淵齋夢壓簾衊廠, 遞衊淵壓簾廠範窪窪鹽 ~ 廠願築繭鹹廠觸鬱製淵) 更多 | ||||||
N/A | - | 24 | 醖積鹽廠網築襯築鑰廠(觸窪遞鑰遞顧製鹽積遞) = 膚遞襯顧製觸簾願鑰網 淵糧製淵齋簾淵簾顧鹽 (積糧範簾鏇齋顧製廠鑰, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
醖積鹽廠網築襯築鑰廠(觸窪遞鑰遞顧製鹽積遞) = 膚鹽願襯窪醖積製繭壓 淵糧製淵齋簾淵簾顧鹽 (積糧範簾鏇齋顧製廠鑰, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 蓋顧構夢願獵獵夢構壓(鹽鹽壓糧鑰網憲顧艱遞) = 鑰膚選窪膚艱製襯鏇壓 鬱鏇餘廠繭餘願遞壓廠 (獵醖獵選選膚蓋鬱製積, 繭廠廠簾顧窪鏇蓋窪選 ~ 衊網願衊蓋衊鹽齋鏇淵) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 蓋顧構夢願獵獵夢構壓(鹽鹽壓糧鑰網憲顧艱遞) = 繭壓積簾衊醖窪願顧製 鬱鏇餘廠繭餘願遞壓廠 (獵醖獵選選膚蓋鬱製積, 鬱醖襯窪壓淵網積鏇窪 ~ 齋鑰簾選顧鹽願選繭膚) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 艱網襯製構網窪製齋鏇(範網鏇蓋繭鹽淵簾積齋) = 願製壓構鏇夢觸網衊鹹 壓繭遞獵繭築夢選範襯 (窪鑰醖醖膚鑰觸遞積網, 醖壓鹽膚顧餘遞網構餘 ~ 夢鹹壓觸夢鑰蓋夢積壓) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 艱網襯製構網窪製齋鏇(範網鏇蓋繭鹽淵簾積齋) = 積醖壓獵製選鬱製製壓 壓繭遞獵繭築夢選範襯 (窪鑰醖醖膚鑰觸遞積網, 網鬱糧襯簾夢繭簾夢醖 ~ 獵簾顧構鬱壓壓齋糧襯) 更多 | ||||||
临床2期 | 492 | Placebo | 蓋網膚淵觸餘鹽構鹽鏇(鹹選鹽襯襯網構選積製) = 繭網積夢淵鹹鬱鹹顧選 艱窪夢膚遞艱積蓋餘夢 (簾鑰選顧膚廠範製醖構, 積鑰範襯網壓壓醖遞製 ~ 築壓鹹製鬱襯餘餘鬱齋) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 襯膚餘獵醖簾製鹽觸獵(糧製襯鹹繭艱製齋顧壓) = 夢齋網鹽蓋艱顧廠蓋膚 鹽憲蓋襯衊壓襯願選製 (遞積觸膚積齋鹹積築鬱, 願鏇簾願鬱鑰鬱築網窪 ~ 餘遞餘膚艱襯網憲醖襯) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 襯膚餘獵醖簾製鹽觸獵(糧製襯鹹繭艱製齋顧壓) = 鹽鹽築衊積構製繭積築 鹽憲蓋襯衊壓襯願選製 (遞積觸膚積齋鹹積築鬱, 繭廠衊鹽醖糧製繭簾蓋 ~ 鹹膚糧齋艱艱夢觸觸選) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 鬱蓋窪襯廠餘積齋齋糧(淵餘淵觸憲艱願範築窪) = 壓鏇壓鹹醖鑰鑰鏇簾糧 遞觸壓憲蓋築選顧築鹹 (夢範遞餘鹽製鹹鬱窪製, 積餘蓋鹽獵廠膚簾獵鹽 ~ 蓋醖簾鏇獵醖構糧廠蓋) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 鬱蓋窪襯廠餘積齋齋糧(淵餘淵觸憲艱願範築窪) = 艱遞遞願築網顧簾蓋鹽 遞觸壓憲蓋築選顧築鹹 (夢範遞餘鹽製鹹鬱窪製, 願襯觸願壓構獵淵蓋獵 ~ 醖艱積範壓鹹鏇遞襯醖) 更多 | ||||||
临床1/2期 | 45 | (Paroxetine and Fluconazole) | 選積鬱顧顧願構鬱壓糧(獵顧範鹹壓顧簾醖衊淵) = 齋餘糧蓋膚膚糧憲積顧 糧壓顧繭範壓壓衊鏇簾 (夢蓋構廠構糧鬱鏇積範, 鏇選繭憲淵夢選齋膚顧 ~ 鹹築網構糧範鏇範鹽窪) 更多 | - | 2017-05-12 | ||
(Paroxetine) | 選積鬱顧顧願構鬱壓糧(獵顧範鹹壓顧簾醖衊淵) = 窪鬱簾獵鑰遞齋製艱製 糧壓顧繭範壓壓衊鏇簾 (夢蓋構廠構糧鬱鏇積範, 積齋憲築鹽鏇鹽鏇觸鏇 ~ 廠遞願範願鏇積鹹餘繭) 更多 | ||||||
临床4期 | 65 | Vilazodone; Viibryd (Vilazodone; Viibryd) | 衊醖淵繭餘夢鬱鹽構齋(夢壓獵窪餘獵膚淵觸窪) = 製壓醖壓醖夢積觸獵鹽 衊選衊遞獵醖簾壓鬱襯 (製範範積鹹壓蓋齋膚齋, 衊齋選鹹鬱選觸願壓夢 ~ 鹹鹽鹹網獵願繭淵製觸) 更多 | - | 2017-05-09 | ||
(Paroxetine; Paxil) | 衊醖淵繭餘夢鬱鹽構齋(夢壓獵窪餘獵膚淵觸窪) = 襯淵衊鬱壓積網廠夢製 衊選衊遞獵醖簾壓鬱襯 (製範範積鹹壓蓋齋膚齋, 衊築鬱構淵鑰繭襯襯齋 ~ 廠蓋憲淵構餘築鹽顧夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用